CABAZITAXEL FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Česká verzia

Authors: Igor Richter ^1,2; Josef Dvořák ²; Věra Hejzlarová ¹; Eva Čermáková ³; Jiří Bartoš ¹
Authors place of work: Onkologické oddělení, Krajská nemocnice Liberec, a. s. ¹; Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha ²; Ústav informatiky a biofyziky, Univerzita Karlova v Praze, Lékařská fakulta v Hradci Králové ³
Published in the journal: Ces Urol 2016; 20(3): 214-220
Category: Original Articles

Summary

Major statement:
Cabazitaxel is a new therapeutic option in patients with metastatic castration-resistant prostate cancer (mCRPC). We presented a retrospective evaluation of toxicity and efficacy in 14 patients with mCRPC treated by cabazitaxel

Aim:
A retrospective evaluation of efficacy and torerance of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Methods:
A total of 14 patients with mCRPC after previous treatment of docetaxel were evaluated. Cabazitaxel was administered in dose 25 mg/m² every 3 weeks concomitantly with daily Prednisolone 10 mg. We evaluated overall survival (OS) and progression free survival (PFS).

Results:
The median of follow-up was 16.5 months. The median of OS was 9.6 months (95 % CI 7.5–22 months). The 2-year OS was described in 23.45 % (95 % CI 0–59 %) of patients. The median of PFS was 5.5 months (95 % CI 2.7– 10.8 months). The toxicity was predominantly grade I or II. Toxicity Grade III – IV: anemia in 2 patients, leucopenia in 1 patient, hematuria in 1 patient, heart failure in 1 patient.

Conclusion:
Cabazitaxel demonstrated favorable profile of toxicity and efficacy in treatment of metastatic castration-resistant prostate cancer in clinical practice.

KEY WORDS:
Prostate cancer, metastazes, chemotherapy, docetaxel, cabazitaxel.

Zdroje

1. Ondruš D, Ondrušová M. Manažement pacientov s kastračne rezistentným metastatickým karcinómom prostaty. Klin Onkol 2015; 28: 24–29.

2. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. JCO 1996; 14: 1756–1764.

3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantron plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512.

4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone plus prednisone for advanced refractory prostatae cancer. N Engl J Med 2004; 351: 1513–1520.

5. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostatae cancer progressing after docetaxel treatment: a randimised open-label trial. Lancet 2010; 376: 1147–1154.

6. Richter I, Dvořák J, Hejzlarová V, et al. Enzalutamid a abirateron v léčbě metastatického kastračně refrakterního karcinomu prostaty po předchozí chemoterapii. Klin Onkol. 2016; 29: 127–132.

7. Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival anp palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Annals of Oncol 2013; 24: 2402–2408.

8. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J clin Oncol 2006; 24: 1633–1642.

9. Tsao CK, Cutting E, Martin J, Oh WK. The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Urol 2014; 6: 97–104.

10. Heidenreich A, Bracarda S, Mason M, et al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostatae cancer: results of the European compassionate-use programme. Eur J Cancer.

11. Mita A, Denis L, Rowinski E, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 723.

12. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormon-senzitive prostate cancer. N Eng J Med 2015; 373: 737–746.

13. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostatae cancer after chemotherapy. N Engj J Med 2012; 367: 1187–1197.

14. de Bono JS, Logothesis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005.

15. Caffo O, Pappagallo G, Brugnara S, et al. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assesment of clinical outcomes and predictive factors. Urology 2012; 79: 644–649.

16. Oudard S, Kramer G, Caffo O, et al. Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. BJU Int 2015; 115: 744–752.

17. Loriot Y, Massard C, Gross-Goupil M, et al. The interval form the last cycle of docetaxel-based chemotherapy to progression is associated with efficacy of subsequent docetaxel in patients with prostatae cancer. Eur J Cancer 2010; 46: 1770–1772.

18. Petrioli R, Francini E, Roviello G, et al. Is there still a place for docetaxel rechallenge in prostate cancer? World J clin Oncol 2015; 6: 99–103.

19. Ryan CJ, Smith MR, de Bono JS, et al. Abirateron in metastatic prostatae cancer without previous chemotherapy. N Engl J Med 2013; 368: 138–148.

20. Beer TM, Amstrong AJ, Rathkof DE, et al. Enzalutamide in metastatic prostatae cancer before chemotherapy. N Engl J Med 2014; 371: 424–433.